Sinclair
- Consolidated Income Statement
- Balance Sheet
- Statement of Changes in Shareholders' Equity
- Cash Flow Statements
- Notes to the Financial Statements
- 1. General information
- 2. Accounting Policies
- 3. Financial risk management
- 4. Segmental information
- 5. Exceptional operating items
- 6. Expenses by nature
- 7. Employees and Directors
- 8. Finance Income and costs
- 9. Taxation on loss on ordinary activities
- 10. Loss for the financial year
- 11. Loss per share
- 12. Goodwill
- 13. Intangible asssets
- 14. Property, plant and equipment
- 15. Investments
- 16. Deferred tax asset
- 17. Inventories
- 18. Trade and other receivables
- 19. Trade and other payables
- 20. Borrowings
- 21. Provisions
- 22. Financial instruments
- 23. Called-up share capital
- 24. Share premium
- 25. Options and warrants over shares of Sinclair Pharma plc
- 26. Share based payments
- 27. Other Reserves
- 28. Cash flows from operating activities
- 29. Operating lease commitments
- 30. Capital commitments
- 31. Related party transactions
- 32. Post balance sheet events
17 Inventories |
||||
|
Group |
Company |
|||
|
2009 £’000 |
2008 £’000 |
2009 £’000 |
2008 £’000 |
|
|
Raw materials |
1,135 |
939 |
– |
– |
|
WIP |
50 |
188 |
– |
– |
|
Finished goods |
2,622 |
2,253 |
– |
– |
|
3,807 |
3,380 |
– |
– |
|